Valuation: Shield Therapeutics plc

Market Cap 5.19Cr 7.07Cr 6.06Cr 5.67Cr 9.74Cr 676.71Cr 9.87Cr 67Cr 26Cr 339.94Cr 27Cr 26Cr 1.12TCr P/E 2026 *
-220x
P/E 2027 * 6.57x
Enterprise Value 7Cr 9.53Cr 8.17Cr 7.64Cr 13Cr 912.27Cr 13Cr 90Cr 35Cr 458.28Cr 36Cr 35Cr 1.52TCr EV / Sales 2026 *
1.26x
EV / Sales 2027 * 0.84x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -
1 day-1.02%
1 week+11.49%
Current month+22.78%
1 month-21.77%
3 months-23.62%
6 months-49.74%
Current year-50.76%
1 week 4.28
Extreme 4.2795
5.2
1 month 3.7
Extreme 3.7
6.4
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Investor Relations Contact - -
General Counsel - 01/01/2026
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap.
14/10/25 Free

Chief Executive Officer

15,47,262 0.1485%
13/02/25 Free

Chief Executive Officer

50,00,000 0.4800%
13/02/25 Buy

Chief Executive Officer

5,75,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%+11.49%-39.83%-50.76% 7.07Cr
+0.90%+3.80%+41.49%-0.78% 8.33TCr
+8.86%+129.20%+435.14%+24.85% 5.79TCr
-1.69%+23.30%-22.30%-36.29% 5.78TCr
-1.46%+0.19%-2.06%+30.50% 5.17TCr
+1.74%+4.43%+12.37%+169.64% 4.93TCr
+1.13%+3.31%+55.61%-17.57% 3.2TCr
+0.46%+6.37%+50.29%+97.27% 2.59TCr
+1.19%+9.17%+2.97%+230.86% 2.27TCr
-0.30%+4.45%+58.29%+118.84% 1.69TCr
Average +0.98%+19.57%+59.20%+56.66% 3.98TCr
Weighted average by Cap. +1.44%+24.97%+80.48%+46.36%

Financials

2026 *2027 *
Net sales 5.54Cr 7.55Cr 6.47Cr 6.05Cr 10Cr 722.53Cr 11Cr 72Cr 28Cr 362.96Cr 28Cr 28Cr 1.2TCr 7.48Cr 10Cr 8.73Cr 8.17Cr 14Cr 975.29Cr 14Cr 97Cr 38Cr 489.93Cr 38Cr 37Cr 1.62TCr
Net income -74.5T -1L -86.98T -81.39T -1L -97.16L -1L -10L -4L -48.81L -4L -4L -1.61Cr 78.6L 1.07Cr 91.77L 85.87L 1.48Cr 102.51Cr 1.49Cr 10Cr 3.96Cr 51Cr 4.02Cr 3.94Cr 170.32Cr
Net Debt 1.81Cr 2.46Cr 2.11Cr 1.97Cr 3.39Cr 235.57Cr 3.43Cr 23Cr 9.09Cr 118.34Cr 9.24Cr 9.04Cr 391.41Cr 1.1Cr 1.49Cr 1.28Cr 1.2Cr 2.06Cr 142.91Cr 2.08Cr 14Cr 5.52Cr 72Cr 5.61Cr 5.49Cr 237.45Cr
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
21/26/21 GBX 4.850 -1.02% 17,38,484
20/26/20 GBX 4.900 +11.36% 80,85,372
19/26/19 GBX 4.400 0.00% 4,36,423
18/26/18 GBX 4.400 0.00% 10,26,860
17/26/17 GBX 4.400 +1.15% 10,78,377
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0485GBP
Average target price
0.1667GBP
Spread / Average Target
+243.65%

Annual profits - Rate of surprise